2024年中国医药流通行业在政策深化与数智化双轮驱动下实现高质量发展。老龄化与健康需求升级推动 服务多元化，医改加速处方外流，院外市场持续扩容，零售终端规模逐渐主导行业增量。报告期内，创 美药业依托扎实的零售终端网络与供应链协同能力，紧抓行业机遇，深化供应链效率与提升精准服务能 力，在高质量发展新周期中实现规模与效益双升。2024年，集团收入录得人民币44.35亿元，净利润达 人民币5328万元，均同比2023年有所增长，集团基本及稀释每股收益亦增长至人民币0.4934元。董事会 建议就截至2024年12月31日止年度派发末期股息每股人民币0.45元(含税)，派息比例高达91%。 2024年，创美药业依托立体化营销网络，携手华润三九（000999）、赫力昂、广药白云山等知名药企构 建完整的产业链和商业生态体系。集团通过品种资源整合、购销渠道优化、数智化物流等核心优势，助 力药企降低渠道拓展难度，促进品牌价值与市场效益提升。同时，集团积极推进千万级厂牌政策，结合 创新的多维度营销策略，实现产品快速流通与高效转化。截至2024年12月31日，集团分销产品12810 种，供应商1206家，分销网络覆盖14429名客 ...

截 至 2024年12月31日止 年 度 之 全 年 業 績 公 告 香 港交易 及結算 所有 限公司 及香港 聯合 交易所 有限公 司對 本公告 的 內 容 概 不 負 責 ， 對 其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失 承擔任何責任 。 Charmacy Pharmaceutical Co., Ltd. 創美藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2289） 年度業績 | 項目 | 附註 | 2024 年度 | 2023 年度 | | --- | --- | --- | --- | | | | 人民幣元 | 人民幣元 | | 一、營業總收入 | | 4,435,460,674.85 | 4,403,633,478.08 | | 其中：營業收入 | 4 | 4,435,460,674.85 | 4,403,633,478.08 | | 二、營業總成本 | | 4,358,586,508.17 | 4,332,543,936.81 | | 其中：營業成本 | 4 | 4,110,698,122.0 ...

Company Recognition and Awards - In the first half of 2024, the Group was recognized as an Excellent Pharmaceutical Logistics and Distribution Enterprise for four consecutive years[1] - The Group has received multiple awards, including the Best Pharmaceutical Cold Chain Logistics Centre for six consecutive years[1] - The Company has been awarded the China Logistics Industry "Golden Ant" Innovation Award for seven consecutive years[1] Market Position and Revenue - The Company ranked 35th among the top 100 wholesalers in China based on revenue generated from its principal business in 2023[1] - The Company ranked 6th among pharmaceutical distribution enterprises in Guangdong Province[1] - Operating revenue for the six months ended June 30, 2024, was RMB 2,347,185, representing a year-on-year increase of 3.44% compared to RMB 2,269,074 in 2023[25] - Revenue from principal business reached RMB 2,325,460, up from RMB 2,241,971 in the previous year, indicating a growth of 3.7%[57] - Revenue from distributors was RMB 1,093,126, slightly up from RMB 1,076,993, while revenue from retail pharmacy stores increased to RMB 1,151,208 from RMB 1,085,417[57] Financial Performance - Total profit for the same period was RMB 38,928, reflecting a year-on-year growth of 10.72% from RMB 35,157 in 2023[25] - Net profit attributable to the shareholders of the parent company was RMB 26,747, a slight increase of 1.50% from RMB 26,353 in 2023[25] - Basic and diluted earnings per share for the six months ended June 30, 2024, were RMB 0.2477, up 1.50% from RMB 0.2440 in 2023[25] - The Group's gross profit increased by 18.85% from RMB 142.35 million for the six months ended June 30, 2023, to RMB 169.18 million for the same period in 2024[61] - The gross profit margin rose from 6.27% to 7.21% due to a 58.49% year-on-year increase in third-party logistics revenue and adjustments in product mix[61] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 3,270,652, showing a 0.71% increase from RMB 3,247,656 as of December 31, 2023[26] - Total liabilities increased by 1.08% to RMB 2,678,497 as of June 30, 2024, compared to RMB 2,649,849 at the end of 2023[26] - Shareholders' equity decreased by 0.95% to RMB 592,154 as of June 30, 2024, down from RMB 597,807 at the end of 2023[26] Distribution Network and Product Range - As of June 30, 2024, the distribution network covered 12,794 customers, an increase of 532 compared to the same period last year, including 611 distributors and 8,516 retail pharmacy stores[36] - The company distributed 11,596 types of products, representing an increase of 838 products compared to the same period last year, with a total of 1,052 suppliers[36] - The total number of products increased to 11,596 for the six months ended June 30, 2024, compared to 10,758 in the same period of 2023, representing a growth of approximately 7.8%[37] Industry Trends and Market Outlook - The pharmaceutical distribution market in China is projected to exceed RMB 4 trillion by 2028, with a compound growth rate of 7%[27] - The out-of-hospital market is expected to reach RMB 1.6 trillion by 2029, potentially matching or exceeding the in-hospital market[29] - The pharmaceutical distribution industry is moving towards high-quality development, with increasing industry concentration and deepening professional services[29] - The ongoing healthcare reforms in China are expected to significantly impact the pharmaceutical industry, shifting the focus from treating diseases to prioritizing people's health[48] Digital Transformation and Technology Integration - The integration of emerging technologies such as AI, big data, and cloud computing is accelerating the digitalisation of the pharmaceutical distribution industry[30] - The Group aims to leverage digital technologies to improve efficiency and quality across the entire pharmaceutical supply chain, including R&D, production, distribution, and service[48] - The focus on digital transformation in the pharmaceutical industry will enhance brand promotion and marketing capabilities[49] Strategic Initiatives and Future Plans - The Company adheres to a development strategy of "Intensive Engagement in Guangdong Province and Extensive Coverage across Surrounding Areas"[1] - The company plans to deepen strategic cooperation with brand manufacturers to capture growth opportunities in non-tendering market products[51] - The company aims to enhance its logistics capabilities and expand third-party logistics business to improve operational efficiency[51] - The Group plans to strengthen risk management and improve operational quality to ensure continuous competitiveness[49] Governance and Compliance - The Company complied with the Corporate Governance Code during the reporting period, with ongoing reviews to enhance governance standards[87] - The Audit Committee has reviewed the unaudited interim results for the six months ended June 30, 2024, ensuring compliance with applicable accounting standards[103] - The Group's financial statements are prepared according to the Accounting Standards for Business Enterprises promulgated by the Ministry of Finance[131] Cash Flow and Financial Management - Cash flow from operating activities showed a net outflow of RMB 174,686,709.65, an improvement compared to the outflow of RMB 228,779,953.32 in the prior period[116] - Cash received from sales of goods and services amounted to RMB 2,016,748,960.28, up from RMB 1,819,538,031.52, marking an increase of about 10.9%[116] - The Group continues to assess its customers' credit and financial positions to minimize credit risks and maintain a sound liquidity position[72] Shareholder Information - The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with the interim dividend of 2023, which was also nil[86] - As of June 30, 2024, Mr. Yao Chuanglong held 34,530,000 H Shares, representing approximately 31.97% of the total issued share capital of 108,000,000 H Shares[92][94] - Ms. You Zeyan holds a beneficial interest in 29,050,000 H Shares, representing approximately 26.90% of the total issued share capital[99] Accounting Policies and Financial Reporting - The Group's accounting policies are aligned with the Accounting Standards for Business Enterprises, ensuring accurate financial reporting[3] - The Group recognizes income when the customer gains control over goods or services, typically three days after shipment[185] - The Group recognizes deferred income tax assets for all unutilized deductible losses within the limit of sufficient taxable income[190]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所産生或因依賴該等 內容而引致的任何損失承擔任何責任。 Charmacy Pharmaceutical Co., Ltd. 創美藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 2289 截至 2024 年 6 月 30 日止六個月之中期業績公告 | --- | --- | --- | --- | |--------------------------|----------------------------------|--------------------------|---------------| | | 截至 6 月 30 \n2024 年 | 日止六個月 \n2023 年 | 同比變動 | | | 人民幣千元 | 人民幣千元 | | | | （未經審核） | （未經審核） | | | 業績 | | | | | 營業收入 | 2,347,185 | 2,269,074 | 3.44% | | 利潤總額 | 38,928 | | 35, ...

Company Performance - Charmacy Pharmaceutical Co., Ltd. ranked 38th among the top 100 wholesale enterprises in China based on revenue from its principal business in 2022[3]. - The company achieved a gross revenue of RMB 271.76 million in 2022, reflecting a significant increase from previous years[10]. - In 2023, the company's revenue reached RMB 292.74 million, with a gross profit margin increasing to 6.65% from 6.51% in 2022[18]. - The total operating revenue reached RMB 4,403,633, an increase from RMB 4,175,279 in 2022, representing a growth of approximately 5.5%[28]. - The total profit for 2023 was RMB 67,420, a decrease from RMB 122,054 in 2022, indicating a decline of about 44.9%[28]. - Net profit attributable to shareholders of the parent company was RMB 51,345 in 2023, down from RMB 90,472 in 2022, reflecting a decrease of approximately 43.2%[28]. - The Group's operating revenue for the year ended December 31, 2023, was RMB 4,403.63 million, an increase of 5.47% from RMB 4,175.28 million for the year ended December 31, 2022[168]. - The principal business revenue amounted to RMB 4,347,522,000, up from RMB 4,140,664,000 in the previous year, reflecting a growth of 5.0%[108]. Logistics and Distribution - The company operates a B2B e-commerce platform "Charmacy e-Medicine" for online ordering, inquiries, and payments[3]. - The logistics system includes a highly efficient delivery mechanism with multiple daily deliveries within specified radii[3]. - The company has received multiple awards for its logistics capabilities, including the Best Pharmaceutical Cold Chain Logistics Centre for five consecutive years[5]. - The company has established medium and large modern pharmaceutical distribution centers in Shantou, Guangzhou, Zhuhai, and Huizhou, equipped with advanced logistics technology to ensure quality and safety of pharmaceuticals[140]. - The company emphasizes the importance of high-quality management and operational excellence in selecting contractors for third-party logistics services[140]. - The Group's third-party pharmaceutical logistics commissioning business saw a year-on-year increase of over 36% in the number of customers and over 72% in corresponding revenue as of December 31, 2023[143]. Market Trends and Strategies - The pharmaceutical distribution market in China is expected to exceed RMB 4 trillion by 2028, with a compound growth rate of 7%[33]. - The company aims to understand market pattern changes and explore industrial chain demands as key strategies for stable growth and high-quality development[23]. - The company plans to leverage competitive advantages in the non-bidding market and enhance digital transformation to drive high-quality development in 2024[24]. - The company aims to improve service quality and create new channels in the pharmaceutical distribution industry to generate long-term value for shareholders[24]. - The company is committed to leveraging digital technology to optimize supply chain logistics and improve last-mile service capabilities[150]. - The company plans to actively seek domestic and international industrial cooperation opportunities to promote high-quality development[156]. Financial Position - The total assets increased to RMB 3,247,656 in 2023 from RMB 2,866,465 in 2022, marking a growth of about 13.3%[28]. - Total liabilities rose to RMB 2,649,849 in 2023, compared to RMB 2,271,403 in 2022, which is an increase of approximately 16.6%[28]. - The gearing ratio increased to 44.28% as of December 31, 2023, compared to 42.75% in the previous year[163]. - Cash and bank deposits increased to RMB112.93 million as of December 31, 2023, from RMB68.86 million as of December 31, 2022[172]. - The Group's net current assets were RMB193.14 million as of December 31, 2023, compared to RMB206.77 million as of December 31, 2022, with a current ratio of 1.07[172]. Governance and Management - The Board resolved on May 31, 2023, to elect Mr. Yan Jingbin as the chairman, replacing Mr. Yao, improving the governance structure[59]. - The responsibilities of the chairman and the CEO are separated to ensure effective checks and balances in governance[72]. - The Company established a nomination committee on November 26, 2015, in accordance with the corporate governance code[72]. - The Company has adopted a Director nomination policy to ensure diversity and suitability of candidates for the Board[75]. - The Audit Committee held two meetings on March 31, 2023, and August 25, 2023, to review the Group's annual results for the year ended December 31, 2023, and interim results for the six months ended June 30, 2023[82]. Employee and Gender Diversity - The board consists of three female directors and six male directors, achieving gender diversity in compliance with the listing rules[106]. - As of December 31, 2023, the company had 451 male employees and 380 female employees, with a gender ratio of 54% male and 46% female[105]. - The company is committed to maintaining and enhancing gender diversity within its workforce[105]. Regulatory Environment - The implementation of the Specification for Logistics Service of Medicinal Product (GB/T 30335-2023) on September 7, 2023, aims to standardize logistics service operations and promote the digital and intelligent transformation of logistics in the pharmaceutical industry[36]. - The New Regulations for pharmaceutical storage and transportation came into effect on July 1, 2023, enhancing the regulatory framework for logistics enterprises[120][125]. - The National Medical Products Administration released a draft guidance in October 2023 to promote the standardization of newly established pharmaceutical wholesale enterprises and third-party logistics, indicating a significant restructuring in the traditional pharmaceutical supply chain[40].

香 港 交 易 及 結 算 所 有限 公 司 及 香 港 聯 合 交易 所 有 限 公 司 對 本 公告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 ， 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 所 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔任何責任。 截 至 2023年12月31日止 年 度 之 全 年 業 績 公 告 年度業績 – 1 – 截至2023年12月31日止年度 | --- | --- | --- | --- | |---------------------------------------------------|-------|---------------|---------------| | | | 2023 年度 | 2022 年度 | | 項目 | 附註 | 人民幣元 | 人民幣元 | | 六、其他綜合收益的稅後淨額 | | | | | 歸屬母公司股東的其他綜合收益的稅後淨額 | | | | | （一）不能重分類進損益的其他綜合收益 | | | ...

860ck Code 2289. HK 中期報告 2023 INTERIM REPORT | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------- ...

- 10 - 本集團的全部業務均位於中國。本集團來自外部客戶的全部營業收入均於中國產生，而本集團所有非流動資 產均位於中國。 7. 所得稅費用 董事會不建議就截至 2023 年 6 月 30 日止六個月派發中期股息（2022 年中期股息：無）。 10. 應收票據 （1）應收票據種類 | --- | --- | --- | --- | |--------------------------------------------------|-------|----------------------------|------------------------------| | 項目 | | 2023 年 6 月 30 日餘額 | 2022 年 12 月 31 日餘額 | | | | （未經審核） | （經審核） | | 銀行承兌匯票 | | | | | 商業承兌匯票 小計 | | 4,012,177.03 4,012,177.03 | 5,348,665.70 | | | | | 5,348,665.70 | | 減：壞賬準備 | | 14,042.62 | 18,720.33 | | 合計 | | 3,998 ...

Compensation and Emoluments - The total emoluments for the five highest-paid individuals amounted to RMB675,691.32, an increase of 8.9% from RMB620,325.08 in the previous year[3]. - Major management's total emoluments reached RMB3,372,674.92, reflecting a 22.6% increase from RMB2,749,145.78 in the prior year[7]. - The Group's emoluments for social insurance, housing fund, and relevant pension costs totaled RMB229,653.14, an increase from RMB182,190.86 in the previous year[3]. Financial Performance - Revenue from pharmaceutical sales for the year was $1,560,606,376.74, up from $1,502,291,335.20 in the previous year, representing a growth of approximately 3.6%[69]. - The total operating revenue for the year was $1,645,219,775.53, compared to $1,576,479,571.62 in the previous year, indicating an increase of about 4.4%[69]. - The company reported gains from the disposal of non-current assets amounting to $65,839,056.46 for the year[73]. - The net profit attributable to the equity shareholders of the parent company for the reporting period was approximately 50.34 million, with a weighted average return on net assets of 16.45%[117]. - The basic earnings per share for the reporting period was 0.8369, and the diluted earnings per share was also 0.8369[117]. - The company’s net profit excluding non-recurring profit and loss was approximately 7.29 million, with a corresponding basic and diluted earnings per share of 0.3708[117]. Accounts Receivable and Bad Debts - Trade receivables at the end of the year were RMB300,333,159.81, a slight decrease from RMB304,238,736.86 at the beginning of the year, indicating a reduction of 1.5%[16]. - The provision for bad debts decreased to RMB3,240,447.62 from RMB5,529,013.97, marking a reduction of 41.5%[16]. - The bad debt provision for trade receivables made on an individual basis was RMB1,115,185.55, accounting for 0.37% of the total book balance[20]. - The collective bad debt provision amounted to RMB2,125,262.07, which is 0.71% of the collective book balance of RMB299,217,974.26[21]. - The total bad debt provision at the end of the year was RMB3,240,447.62, reflecting a significant increase from the previous year's provision[24]. Shareholding and Corporate Governance - Public shareholding accounted for 21.62% of the total issued share capital, which is below the minimum requirement of 25%[13]. - The controlling shareholder, Mr. Yao Chuanglong, confirmed compliance with the non-competition deed for the year ended December 31, 2022[34]. - The independent non-executive Directors reviewed compliance status and confirmed that the controlling shareholder adhered to the non-competition deed[34]. - The independent non-executive directors confirmed that the terms of continuing connected transactions are fair and reasonable, aligning with the overall interests of the shareholders[51]. Assets and Liabilities - Total current assets increased to RMB2,462,361,349.11 as of December 31, 2022, up from RMB2,238,222,282.83 in 2021, representing a growth of approximately 10%[154]. - Total non-current assets decreased to RMB403,523,794.93 in 2022 from RMB524,869,239.03 in 2021, reflecting a decline of approximately 23%[156]. - Total liabilities amounted to RMB2,271,402,825.64 as of December 31, 2022, slightly up from RMB2,258,989,542.23 in 2021, showing a marginal increase of about 0.6%[158]. - Total shareholders' equity attributable to the shareholders of the parent company increased to RMB594,482,318.40 in 2022, compared to RMB504,101,979.63 in 2021, marking a growth of approximately 18%[159]. Cash Flow and Financing Activities - Cash flow from operating activities totaled RMB3,696,584,127.65 in 2022, up from RMB3,282,927,789.69 in 2021, indicating a growth of 12.63%[189]. - The company reported a net cash flow from operating activities of RMB44,050,304.46 in 2022, a turnaround from a negative cash flow of RMB-19,543,392.21 in 2021[189]. - Cash received from borrowings in financing activities decreased to RMB825,887,076.38 in 2022 from RMB957,970,978.42 in 2021, a decline of 13.8%[191]. - Net cash flow from financing activities turned negative at RMB-191,211,558.73 in 2022, compared to a positive RMB74,400,884.77 in 2021[191]. Internal Control and Audit - The Board of Supervisors has conducted a review and found that the company has established an appropriate internal control system that operates effectively[126]. - The company’s connected transactions in 2022 have been filed, audited, announced, and approved by independent shareholders in accordance with the Listing Rules[125]. - The audit opinion does not cover other information and does not express any form of assurance conclusion on it[145]. - The overall presentation, structure, and content of the financial statements must be evaluated to ensure fair representation of underlying transactions[148]. Inventory Management - The balance of inventories as of December 31, 2022, was RMB590.002 million, with a provision for impairment of inventories amounting to RMB3.1483 million, leading to a carrying amount of RMB586.8537 million[139]. - The company made full provisions for inventories that would expire within 180 days and remained unsold prior to the reporting date[139]. - The management's internal controls regarding the validity period and stock-in time of inventories were tested in the SAP system[139].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分 內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 截 至 2022年12月31日止 年 度 之 全 年 業 績 公 告 年度業績 合併利潤表 - 2 - 合併資産負債表 - 4 - - 5 - 1. 一般資料 合併財務報表以人民幣呈列，其亦為本公司功能貨幣。 CHARMACY PHARMACEUTICAL CO., LTD. 創美藥業股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2289） | --- | --- | |-------|----------------------------------------------------------------------------------------------| | | | | | 財務摘要 | | • | 於 2022 年，本集團的營業收入為人民幣 4,175.28 百萬元，較 2021 年的人民幣 3,793.62 百萬元增 ...